Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial

AIMS: To evaluate the effects of separate and combined use of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor dapagliflozin and the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) exenatide on measures of kidney function. METHODS: In this prespecified secondary analysis of the DECREASE trial...

Descripción completa

Detalles Bibliográficos
Autores principales: van Ruiten, Charlotte C., van der Aart‐van der Beek, Annemarie B, IJzerman, Richard G., Nieuwdorp, Max, Hoogenberg, Klaas, van Raalte, Daniël H, Heerspink, Hiddo J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360098/
https://www.ncbi.nlm.nih.gov/pubmed/33908691
http://dx.doi.org/10.1111/dom.14410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360098/
https://www.ncbi.nlm.nih.gov/pubmed/33908691
http://dx.doi.org/10.1111/dom.14410

Ejemplares similares